BEYOND AIR INC (XAIR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$2.18-6.44%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · XAIR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“Our strong revenue growth in the quarter ended September 30, 2026 reflects continued adoption of LungFit PH and the value hospitals see in our cylinder-free nitric oxide technology,” said Robert Goo…
Stated in 2 of 2 supplied quarters. Management reported: “The growth was driven by increased demand for LungFit PH in both the U.S. and international markets.” “The preliminary revenue represents an increase of approximately 30% compared with the quarter ended June 30, 2026 and 27% compared with the same quarter last year, and reflects the successful rollout of the Company’s enhanced commercial execution strategy for LungFit PH.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We believe these efforts position us well for the anticipated launch of our second-generation LungFit PH system, pending FDA approval, and support our objective of expanding adoption of LungFit PH ov…”
“Our fiscal 2026 performance, including the 107% revenue growth, strong customer retention of over 90% and new hospital customer wins, reflect that focus and positions us for what we believe could be…”
We continue to be pleased with the progress we are seeing with the ongoing PMA supplement process.
Stated in 2 of 2 supplied quarters. Management reported: “|| ○ | International submissions for LungFit PH remain on track with local partners.” “We continue to be pleased with the progress we are seeing with the ongoing PMA supplement process.”
“|| ○ | International submissions for LungFit PH remain on track with local partners.”
“[/TABLE] [TABLE] ○ | With a broader label, including use during patient transport by air and ground, the second-generation system is expected to increase the total addressable U.S. market for the Lun…”
The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval.
Stated in 2 of 2 supplied quarters. Management reported: “Financial Guidance The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which does not include any revenue from the second-generation LungFit PH system.” “The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval.”
“Financial Guidance The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which does not include any revenue from the second-generation LungFit PH system.”
“For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and including the comm…”
Subsequent to quarter-end, the Company strengthened its balance sheet with an up to $30.1 million financing, consisting of $10.2 million in upfront gross proceeds and up to an additional $20.0 millio…
Stated in 1 of 2 supplied quarters. Management reported: “The private placement is expected to result in aggregate gross proceeds to the Company of up to $30.1 million, before deducting placement agent fees and other offering expenses payable by the Company, assuming all Series A warrants and all Series B warrants are exercised for cash, of which there can be no guarantee.” “Subsequent to quarter-end, the Company strengthened its balance sheet with an up to $30.1 million financing, consisting of $10.2 million in upfront gross proceeds and up to an additional $20.0 million from the potential exercise of short- and long-term warrants, including $10.0 million tied to FDA approval of the second-generation LungFit PH system.”
“Subsequent to quarter-end, the Company strengthened its balance sheet with an up to $30.1 million financing, consisting of $10.2 million in upfront gross proceeds and up to an additional $20.0 millio…”
Expand LungFit PH customer adoption and commercial reach through stronger execution, hospital access, and international distribution.
Over the trailing year it converted 0.80x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
30 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.